BLRX - BioLineRx Ltd Company Balance Sheet Assets

Symbol and logo of brand BioLineRx Corp (BLRX)

The price action of BioLineRx Ltd. (BLRX) total assets is 38.35. BioLineRx Ltd. promotes cancer treatments and stem cell activation methods through partnerships with global behemoths, which facilitates the integration of Aphexda into US medicine. Sales of this drug generate operating cash flow, supporting financial stability. However, a narrow product pipeline and expansion challenges may hinder the return on investment.

BLRX: BioLineRx Ltd Aggregate Company Assets 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for BioLineRx Corp (BLRX)

- price and consensus price forecast:
Share Price biolinerx.com|BLRX - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization BioLineRx Corporation|BLRX - Enterprise Value
- book capitalization data:
Net Asset Value per Share BioLineRx|BLRX - Company Book Value|Capitalization to Book Value Ratio biolinerx.com|BLRX - Company Total Assets
- debt and liquidity data:
Debt to Capital BioLineRx Ltd.|BLRX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital BioLineRx Corporation|BLRX - Company Aggregate Debts|Debts to Book Capitalization BioLineRx Corporation
Fundamental valuation:biolinerx.com, BLRX
Finished products of BioLineRx Corporation

A reverse calculation of total resources via return on assets (ROA) demonstrates the sensitivity of the capital base to the efficiency of profit generation from available funds. This indicator reflects the total asset value of BioLineRx Ltd. (BLRX), where the asset trajectory based on ROA allows for an assessment of the company's ability to scale the commercialization of Aphexda and expand clinical trials without critical resource value dilution amid competition.

Main competitors

incyte.com (INCY) - Total Business Assets|HUTCHMED - Company Total Assets|Company Balance Sheet Assets Nuvation Bio Inc|Day One Bio - Company Total Assets|Company Assets MNPR (Monopar Corp)|INBX - Aggregate Company Assets|Total Business Assets I-Mab Biopharma Co., Ltd. IMAB|FENC (Fennec Pharmaceuticals Inc.) - Company Total Assets|HRTX: Company Assets|Aggregate Company Assets Nuvectis NVCT|Coherus BioSciences, Inc. (CHRS) - Aggregate Asset Value|CRBP (Corbus Pharmaceuticals) - Company Total Assets|Company Total Assets CRDF|Aggregate Company Assets BeyondSpring (BYSI)|Aggregate Company Assets bioatla.com BCAB|Cumulative Company Assets Lixte Biotechnology Holdings|Citius Pharmaceuticals Inc. - Aggregate Asset Value|CLRB (Cellectar Biosciences) - Aggregate Company Assets|CANF: Company Assets|Aggregate Company Assets aprea.com|Kazia Therapeutics Limited (KZIA) - Total Business Assets|Company Total Assets SLXN|Cumulative Company Assets NCNA|Chimerix, Inc. - Aggregate Company Assets|Company Assets CYCC (cyclacel.com)|Aggregate Company Assets G1 Therapeutics GTHX|Kronos Bio Inc - Aggregate Company Assets|KTRA (Kintara) - Aggregate Company Assets|ONCT - Company Assets|Company Total Assets PRTG (Portage Biotech Inc.)